A significant discovery has changed the narrative of aging: proline, a simple amino acid, is now at the forefront of scientific exploration to restore aging cells. This discovery is far from the field of science fiction, introducing a new chapter in aging research, revealing the potential of Proline to reverse time at the cellular level. By introducing proline into cells that have stopped its division cycle and shown signs of aging, the researchers introduced a significant enhancement of cell function. This journey of rejuvenating the core of proline not only extends life, but also enriches its quality, greatly alleviating the future of aging for the decline of aging, adding exciting possibilities to extend its quality.
In a groundbreaking study that could create a trend in our ongoing struggle with the aging process, Professor Stelios and Readis of the University of Buffalo, together with a team of researchers, reveals how the amino acid proline will make new Life is injected into the aging mesenchymal stem cells (MSCs) of newborns. This study, detailed in the Cell Report, highlights the potential of proline supplementation to significantly enhance mitochondrial function and promote mitochondria and provides a beacon of hope when reversing the signs of aging.
Mesenchymal stem cells were found to have ceased division and showed signs of aging, and their ability to produce proline, a key player in cellular stress response and bioenergy. Professor Andreadis elucidated this finding, noting that “aging MSCs exhibit severely impaired mitochondrial respiratory chain activity, which is combined with the accumulation of depolarized mitochondria due to defective mitochondria.” This observation emphasizes proly The key role of acid in maintaining cell viability.
The researchers have adopted an innovative approach to revitalize these cells. By supplementing aged MSCs with proline, they observed a significant improvement in mitochondrial function. This process is caused by the activation of AMP-activated protein kinase alpha (AMPK) and upregulation of Parkin, the key component of the initiation of mitochondria – the cell method is to clean the chamber by selectively degrading damaged mitochondria. room method. This not only enhances mitochondrial clearance, but also reduces several aging indicators such as DNA damage and β-galactosidase activity associated with aging.
The research team delved into their methodological approach, providing proline to older MSCs in a carefully controlled environment, thus monitoring the effects over time. Professor Andreadis shared: “Proline induces mitochondria by activating AMPK and upregulating Parkin expression, enhancing mitochondrial clearance and ultimately restoring cell metabolism.” This insight is particularly convincing, suggesting that seemingly simple molecules to cells Levels of complex aging processes have profound effects.
Interestingly, the team also found that the positive effect of supplementing proline was not dependent on the breakdown of proline dehydrogenase (PODH), suggesting that the presence of proline itself, but not its metabolites, is to restore aging cells. The key. Professor Andreadis noted that “knockdown of PODH has no significant effect on proline’s ability to restore mitochondrial function and autophagic flux in senescent cells.”
This study not only elucidates the complex dance of cell metabolism in the context of aging, but also opens the door to novel therapeutic strategies aimed at alleviating mitochondrial dysfunction associated with aging. Restoring the regenerative potential of aged stem cells by supplementing proline may lead to breakthrough anti-aging therapies.
Professor Stelios and Readis and his team cleverly blended meticulous observations with innovative experiments, enhancing our understanding of metabolic interventions that fight age-related diseases. In their hands, proline transitions from molecules of interest to promising drugs to expand the range of health and rejuvenate aging tissue, marking a significant advance in the science of aging. Their research not only emphasizes the potential of Proline, but also raises possibilities in a new chapter in the struggle against the aging process.
Journal Reference
Debanik Choudhury, Na Rong, Hamsa Vardini Senthil Kumar et al., “Proline restores mitochondrial function and reverses the marker of senescence in senescent cells”, Cell Reslest, Vol. 43, no. 113738. doi: https://doi.org/10.1016/j.celrep.2024.113738
About the Author
Stelios T. and Readis Received his Master of Applied Mathematics, as well as his MS and PhD. Degree in Chemical Engineering from the University of Michigan. He then received a postdoctoral training at the Center for Medical Engineering at Harvard Medical School, where he worked in gene therapy, tissue engineering, and regenerative medicine. Currently, he serves as the Center for Excellence in Bioinformatics and Life Sciences at SUNY Buffalo University and the Center for Excellence in Bioinformatics and Life Sciences at SUNY. He has served as Director of Stem Cells in the Regenerative Medicine (SIMMIRM) Training Program, which is funded by NYSTEM to train students in stem cell biology and bioengineering of stem cells in regenerative medicine and the application of applications (2016-2021). He is the founding director of the Center for Cell, Gene and Tissue Engineering (CGTE), established two years ago, aiming to promote interdisciplinary research and education in these areas. From 2012 to 2018, he served as chairman of the CBE department for two terms.
His research interests range from basic to a wide range of preclinical/translational studies. He has made important research contributions in the field of stem cell bioengineering. Blood vessels, skin, muscle and gland tissue engineering and regeneration; molecular design of biomaterials; protein and gene delivery, and stem cell aging and aging. He co-founded a startup (Angiograft, LLC) to commercialize cell-free vascular grafts that were performed in his lab as arterial replacement grafts for the treatment of cardiovascular disease. He has been invited to speak among spokespersons in many departments and many departments across the country and internationally. His work has led to 145 peer-reviewed publications, 32 conference litigation, 90 invited speeches and more than 300 conference speeches. His group’s publications appear in top journals, Journal of Virology, Journal of Research Dermatology, Gene Therapy, Biomaterials, Tissue Engineering, Biomedical Engineering Annual Reviews, and more.
His work has been providing funding for over 20 years from federal, state and private foundation sources including NIH, NSF, New York State Stem Cell Fund (NYSTEM), JDRF, JR. OISHEI Foundation and Whittaker Foundation, totaling over $25 . mega. Recently, he led a team of UB and RPCI investigators who received a grant from NYSTEM to launch a new training program for regenerative medical stem cells (SCIRM) stem cells.
Due to his work, he has received several awards, including the Whitaker Foundation Young Fellow Award (1999), the NSF Career Award (2000), the Distinguished Scholar Young Noung Novender Award (UB, 2003), Distinguished Scholar: Continuing Achievement Award (UB, 2009) and the SUNY Secretary’s Scholarship Excellence Award (2014). He was elected to the Institute of Medical and Bioengineering (AIMBE, 2009) Society of Biomedical Engineering (BMES, 2016), Institute of Chemical Engineers (AICHE, 2022), and American Association for Scientific Development (AAAS, 2022). In 2018, he was promoted to the rank of Distinguished Professor at SUNY, the highest ranking in the SUNY university and university system.
He mentored more than 115 trainees, including 35 PhDs. and 22 students, 7 postdoctoral fellows and more than 55 undergraduate researchers. His previous eight doctoral students at top research universities (Georgetown, Oklahoma U, Auburn U, the National Institute of Standards and Technology (NIST), South Florida UB, UB, IIT Kanpur, Beijing Capital IIT Kanpur , Beijing, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB, UB) holds the position of teacher. Others hold postdoctoral positions at top universities (Harvard, Stanford, Johns Hopkins, U Penn); or leading drug/biotech companies (Merck, Bristol Menu, Biogenes, Shire Medicines Research and leadership positions in Lifetechnologies, Lyndra Therapeutics, Medimmune, etc.
